STALEVO 50/12.5/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

stalevo 50/12.5/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle

sandoz pty ltd - levodopa, quantity: 50 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Levodopa and Carbidopa CR Actavis New Zealand - English - Medsafe (Medicines Safety Authority)

levodopa and carbidopa cr actavis

teva pharma (new zealand) limited - carbidopa 50mg; levodopa 200mg - modified release tablet - 200mg/50mg - active: carbidopa 50mg levodopa 200mg excipient: colloidal silicon dioxide hypromellose iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose - levodopa and carbidopa cr actavis tablets are indicated for: - idiopathic parkinson's disease - postencephalic parkinsonism - symptomatic parkinsonism (carbon monoxide or manganese intoxication) - patients with parkinson's disease or parkinsonism who are taking vitamin preparations that contain pyridoxine - to reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterised by end-of-dose deterioration ("wearing-off" phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances.

CENTEVO levodopa/carbidopa/entacapone 200 mg/50 mg/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

centevo levodopa/carbidopa/entacapone 200 mg/50 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - centevo (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CENTEVO levodopa/carbidopa/entacapone 175 mg/43.75 mg/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

centevo levodopa/carbidopa/entacapone 175 mg/43.75 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 175 mg; carbidopa monohydrate, quantity: 47.2 mg (equivalent: carbidopa, qty 43.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - centevo (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CENTEVO levodopa/carbidopa/entacapone 150 mg/37.5 mg/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

centevo levodopa/carbidopa/entacapone 150 mg/37.5 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 150 mg; carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; polysorbate 80; iron oxide red; carmoisine aluminium lake - centevo (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CENTEVO levodopa/carbidopa/entacapone 125 mg/31.25 mg/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

centevo levodopa/carbidopa/entacapone 125 mg/31.25 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 125 mg; carbidopa monohydrate, quantity: 33.8 mg (equivalent: carbidopa, qty 31.25 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red - centevo (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CENTEVO levodopa/carbidopa/entacapone 100 mg/25 mg/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

centevo levodopa/carbidopa/entacapone 100 mg/25 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; polysorbate 80; allura red ac aluminium lake; carmine - centevo (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CENTEVO levodopa/carbidopa/entacapone 75 mg/18.75 mg/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

centevo levodopa/carbidopa/entacapone 75 mg/18.75 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red - centevo (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CENTEVO levodopa/carbidopa/entacapone 50 mg/12.5 mg/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

centevo levodopa/carbidopa/entacapone 50 mg/12.5 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 50 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - centevo (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

RATIO-LEVODOPA/CARBIDOPA TABLET Canada - English - Health Canada

ratio-levodopa/carbidopa tablet

ratiopharm inc division of teva canada limited - levodopa; carbidopa - tablet - 250mg; 25mg - levodopa 250mg; carbidopa 25mg - dopamine precursors